Ferrum Lek solution for intramuscular injection of ampoules 2 ml 5 pcs
Condition: New product
992 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Iron (III) hydroxide polymaltozane
Release form
Solution
Composition
Active ingredient: iron (III) hydroxide polyisomaltozat Concentration of active ingredient (mg): 100 mg
Pharmacological effect
Antianemic drug. In the preparation, iron is in the form of a complex compound of iron (iii) hydroxide polyisomaltose. This macromolecular complex is stable and does not release iron in the form of free ions. The complex is similar in structure to the natural compound of iron - ferritin. iron (iii) hydroxide polyisomaltozate does not possess prooxidant properties that are inherent in iron salts (ii). iron, which is part of the drug, quickly compensates for the deficiency of this element in the body (including with iron deficiency anemia), restores hemoglobin (hb). with the use of the drug, there is a gradual regression of clinical (weakness, fatigue, dizziness, tachycardia, pain and dryness of the skin) and laboratory symptoms of iron deficiency.
Pharmacokinetics
After i / m administration of the drug, iron quickly enters the bloodstream: 15% of the dose after 15 minutes, 44% of the dose after 30 minutes. The iron in combination with transferrin is transferred to the cells of the body, where it is used to synthesize hemoglobin, myoglobin and some enzymes.
Indications
Iron deficiency anemia (reduction of hemoglobin in the blood due to impaired delivery, absorption or excretion of iron) of various etiologies (causes).
Contraindications
Hemochromatosis (metabolic iron-containing pigments) and hemosiderosis (deposition of a dark yellow iron-containing pigment in the skin), as well as anemia (decrease in hemoglobin in the blood), not associated with iron deficiency.
Precautionary measures
The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C; do not freeze.
Use during pregnancy and lactation
Parenteral administration of the drug is contraindicated in the first trimester of pregnancy. In the II and III trimesters of pregnancy and during breastfeeding, the drug is prescribed only if the expected benefit to the mother outweighs the potential risk to the fetus or infant.
Dosage and administration
Deep intramuscularly every other day for 2 ml.The maximum daily dose for intramuscular administration for adults is 4 ml, for children weighing up to 5 kg it is 0.5 ml, body weight 5-10 kg is 1 ml. Intravenous to adults: on the 1st day - 2.5 ml (! / 2 ampoules), 2nd day - 5 ml (1 ampoule) and 3rd - 10 ml (2 ampoules), then 2 times a week for 10 ml.
Side effects
After the first injection, it is recommended to monitor patients in order to identify the reaction to the drug.
Overdose
Symptoms: An overdose of iron preparations can lead to acute iron overload and hemosiderosis. Treatment: symptomatic therapy. As an antidote, it is administered intravenously slowly (15 mg / kg / h) of deferoxamine, depending on the severity of the overdose, but not more than 80 mg / kg / day. Hemodialysis is ineffective.
Interaction with other drugs
Ferrum Lek for i / m injections should not be used simultaneously with iron preparations for oral administration. Simultaneous use of the drug Ferrum Lek with ACE inhibitors may cause an increase in the systemic effects of parenteral iron preparations.
special instructions
The drug should be used only in a hospital setting. When prescribing Ferrum Lek, laboratory tests should be carried out: general blood count and determination of the serum ferritin level; it is necessary to exclude a violation of iron absorption. Treatment with oral forms of iron-containing drugs should be started no earlier than 5 days after the last injection of Ferrum Lek. The contents of the ampoules should not be mixed with other drugs.